TokenPost topic

Kalaris Therapeutics

1 TokenPost story is tagged Kalaris Therapeutics. The newest appear first.

Latest Kalaris Therapeutics stories

• Kalaris Posts $0.46 Q3 GAAP Loss Per Share as Net Loss Narrows

  Cash, cash equivalents and marketable securities totaled $82.9 million at quarter-end, enough to support operations into 2028 under current operating plans.

  Nov 11, 2026, 9:47 AM EST · Business